Additional File 2. Secondary outcomes: EQ5D, VAS, NMS-Quest

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Medido** | **Control** | **Effect** **M - C** | **P-value of****Difference scores +** |
| **BL (n=36)** | **3 months (n=24)** | **6 months (n=29)** | **ΔBL-6 months** | **BL (n=51)** | **3 months (n=36)** | **6 months (n=45)** | **ΔBL-6 months** | **Effect** **(95%CI)** |  |
| **EQ5D**[-0.33-1.00] | 0.62(0.03) | 0.61(0.03) | 0.59(0.04) | **-0.02****(0.03)** | 0.70(0.03) | 0.66(0.03) | 0.67(0.3) | **-0.04****(0.03)** | **0.01****(-0.06; 0.08)** | **0.475** |
|   |
| **VAS**[0-10]  | 6.3(0.2) | 6.2(0.2) | 6.7(0.2) | **0.4****(0.3)** | 6.5(0.2) | 6.6(0.2) | 6.5(0.2) | **-0.04****(0.32)** | **0.42****-0.22;1.05** | **0.057** |
| **NMS-Quest**[0-30] | 12.4(0.8) | 12.5(0.8) | 13.6(0.9) | **1.2****(0.7)** | 9.9(0.6) | 10.1(0.7) | 9.8(0.7) | **-0.1****0.9** | **1.3****(-0.5; 3.0)** | **0.095** |
| Table A2. Outcome EQ5D, VAS and NMS questionnaire data. Analysed by ‘Repeated measurement analysis’. Scores presented as means (SE). BL: baseline score, ΔBL-6mnd: difference between 6 months and baseline. Effect BL-6mnd: difference ΔBL-6mnd intervention – ΔBL-6 months control. NMS-Quest: lower scores represents better outcome.+ p-value based on ‘time x measurement’ analysis of difference score between baseline and follow-up. |